Suggested remit - to appraise the clinical and cost effectiveness of Pembrolizumab within its marketing authorisation for treating untreated, locally advanced or metastatic, triple negative breast cancer
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA 2018
|
| ID number |
1546
|
Provisional Schedule
| Final draft guidance |
25 May 2022 - 10 June 2022 |
| Expected publication |
29 June 2022 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors |
Merck Sharp & Dohme |
| Patient carer groups |
Breast Cancer Now |
| Professional groups |
Association of Cancer Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
UK Breast Cancer Group |
| |
UK Clinical Pharmacy Association |
| Comparator companies |
Janssen-Cilag |
| |
Pfizer |
| |
Roche |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
12 April 2022
|
Committee meeting: 2 |
|
08 March 2022 - 29 March 2022
|
Draft guidance |
|
15 February 2022
|
Committee meeting: 1 |
|
24 November 2021
|
The committee meeting for this appraisal has been scheduled for 15 February 2022. |
|
05 May 2021
|
Following an update from the company, NICE will reschedule this appraisal and the committee meeting scheduled for 6 July 2021 will now take place at a later date. This webpage will be updated when the new dates are confirmed. |
|
27 October 2020
|
Invitation to participate |
|
16 September 2020 - 07 October 2020
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
09 June 2020
|
The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during late October 2020 when we will write to you about how you can get involved. |
|
28 November 2019
|
The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab in combination for untreated, locally advanced or metastatic, triple negative breast cancer.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during late- May 2020 when we will write to you about how you can get involved. |
|
10 June 2019 - 08 July 2019
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
17 October 2018
|
In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual